Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694275 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03694275 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 20 participants.
The verdict
NCT03694275, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
Interventions
- DRUG Soticlestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694275
The ClinicalTrials.gov registry entry for NCT03694275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Soticlestat is the first listed.
NCT03694275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03694275 about?
NCT03694275 is a clinical study titled "A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)". The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
What is the current status of trial NCT03694275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-09-10. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03694275?
The interventions under investigation include: Soticlestat (DRUG).
Who is sponsoring clinical trial NCT03694275?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.